Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01800682 · ClinicalTrials.gov registry record · Phase 1
A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT01800682 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 30 participants.
The verdict
NCT01800682, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the dose proportionality of the pharmacokinetics (explores what the body does to the drug) of tramadol in healthy adult participants.
Interventions
- DRUG Tramodol Extended-Release (ER)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2011-07 |
| Est. Completion | 2011-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01800682
The ClinicalTrials.gov registry entry for NCT01800682 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Tramodol Extended-Release (ER) is the first listed.
NCT01800682 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01800682 about?
NCT01800682 is a clinical study titled "A Pharmacokinetic Study to Evaluate the Dose-Proportionality of Tramadol (ULTRAM) Extended-Release (ER) in Healthy Participants". The purpose of this study is to evaluate the dose proportionality of the pharmacokinetics (explores what the body does to the drug) of tramadol in healthy adult participants.
What is the current status of trial NCT01800682?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2011-07. Estimated completion is 2011-09.
What interventions are being tested in trial NCT01800682?
The interventions under investigation include: Tramodol Extended-Release (ER) (DRUG).
Who is sponsoring clinical trial NCT01800682?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.